Source: Quoin Pharmaceuticals, Inc. 11/2/2021
Addition of Bi-Functional Protein Is Complementary to Lead Asset QRX003 for Netherton Syndrome
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the
“Company” or “Quoin”), a specialty pharmaceutical company focused on
rare and orphan diseases, today announced that it has signed an
agreement with Queensland University of Technology, Australia (QUT). The
agreement is for an exclusive option to a bi-functional protein that
has shown promising in-vitro data as a potential treatment for Netherton
Syndrome.
Under the terms of the deal, Quoin will fund a pre-clinical program at QUT. Upon completion of the program, Quoin has the option to sign an exclusive global license to the protein and all of its associated intellectual property. The terms of the deal do not require Quoin to pay any upfront license or milestone fees. Upon approval of the completed product, Quoin will pay QUT a mid-single digital royalty on sales.
Dr. Michael Myers, Chief Executive Officer of Quoin, commented, “We are excited to have entered into this partnership with QUT. Quoin believes that the in-licensing of this protein is complementary to our lead asset, QRX003 for Netherton Syndrome, and further strengthens our leadership position in the development of potential treatments for this devastating disease. Following our recent merger with Cellect Biotechnology Ltd., we have a strong balance sheet to support the execution of our strategic plans.”
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is an emerging specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises three products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa and others. For more information, go to: www.quoinpharma.com.
No comments:
Post a Comment